Exero Medical

Early Detection of Postoperative Anastomotic Leaks

Health Tech & Life Sciences
Active
Seed Or Yehuda, Israel Founded 2018
Last updated 2026-06-18
Total raised
$16.1M
Last: 2025-02
Stage
Seed
Founded
2018
Headcount
13
HQ
Or Yehuda, Israel
Sector
Health Tech & Life Sciences

About

Exero Medical develops a biodegradable wireless sensor for early detection of anastomotic leaks following GI surgery. The system is designed to prevent complications by warning physicians of potential leaks, allowing early intervention. Anastomotic leaks are a common, life-threatening complication of GI surgeries, such as colorectal and bariatric surgeries. Early detection before the clinical manifestation of an anastomotic leak is key to a favorable outcome, but diagnosis at this stage is difficult. This delay in diagnosis affects both mortality rates and economic burdens. Exero Medicals system deploys a sensor that continuously monitors the condition of the anastomosis area, enabling early detection and preventive action before the patients condition deteriorates. In December 2020, the FDA granted breakthrough device designation for Exero Medicals wireless system designed for the early detection of potentially lethal anastomotic leaks following gastrointestinal surgery.

Funding history · 5 rounds · $16.1M total

Q&A

What is Exero Medical's primary focus?
Exero Medical develops a biodegradable wireless sensor for the early detection of anastomotic leaks following GI surgery, aiming to prevent complications through early intervention.
When was Exero Medical founded?
Exero Medical was founded in September 2018.
How many employees does Exero Medical have?
Exero Medical has an employee count in the 11-50 range.
What was Exero Medical's most recent funding round?
In February 2025, Exero Medical raised $12,700,000. The lead investors were Tech Council Ventures and Longevity Venture Partners
What is Exero Medical's total funding to date?
Exero Medical has raised a total of $16,100,000 USD across all funding rounds.
What is the current product stage of Exero Medical's technology?
Exero Medical's product is currently in the clinical trial stage.
Which investors participated in Exero Medical's November 2018 funding round?
In November 2018, investors included Israel Innovation Authority.
Has Exero Medical received any special designations for its device?
In December 2020, the FDA granted breakthrough device designation for Exero Medical's wireless system for early detection of anastomotic leaks.

Team · 1

Founder · Founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote Monitoring
Technologies
SensingMaterials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

medical-technologiessurgeryalert-systembiodegradablehospitalsmedical-devicessensorspatent-pendingleak-detectionmedical-devicesremote-sensingmonitoringsurgeonsremote-monitoringgastroenterologydigital-healthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteexeromedical.com
LinkedInlinkedin.com/company/18838545

Identifiers & details

Founded2018-9
Employees (exact)13

Radar intelligence

Patents

EPO3

Web history (Wayback)

Domainexeromedical.com

Certificate / subdomain footprint

Subdomains9